Deazaguanylation is a nucleobase-protein conjugation required for type IV CBASS immunity

Journal:

Science

Published:

2025-09-25

DOI:

10.1126/science.adx6053

Affiliations:

5

Authors:

6

Go to article

Institutions	Authors	Share
University of California, San Francisco (UCSF), United States of America (USA)	2.000000	0.33
Harvard University, United States of America (USA)	2.000000	0.33
Harvard Medical School (HMS), United States of America (USA)	0.833333	0.14
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	0.833333	0.14
Parker Institute for Cancer Immunotherapy, United States of America (USA)	0.333333	0.06

Interested in Genetics?